New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Sanofi

SNY

Healthcare Drug Manufacturers General

Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024.

Revenue
+13.9%
EPS
+8.21%
Free cash flow
+99.6%
Total debt
−11.2%

Quarter to September 2026, against a year earlier

46.62 0.56 +1.22%
Market cap
$111.3B
P/E
22.8×
Fwd P/E FY26e
—
Dividend yield
5.25%
F-score
7/9
ROIC
7.05%
Net debt / EBITDA
0.8×
Payout ratio
1.2×

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Revenue
59,094.64 56,955.87 54,841.03 52,854.47

+8 more TTM periods

Gross Profit
43,399.49 41,452.87 39,448.25 38,090.85
Operating Income
11,068.56 10,387.73 9,829.12 9,830.73
EBT
7,151.01 6,415.04 7,057.25 6,986.40
Income after Tax
5,142.25 4,986.88 5,892.37 5,806.34
Net Income Common
4,885.67 4,683.76 8,756.50 8,839.63
EPS (Diluted)
2.02 1.91 3.58 3.60
Shares (Diluted, Weighted)
2,413.20 2,422.25 2,432.50 2,447.35
Gross Margin
73.44% 72.78% 71.93% 72.07%
EBIT Margin
18.73% 18.24% 17.92% 18.60%
Net Profit Margin
8.27% 8.22% 15.97% 16.72%
Free Cash Flow Margin
40.26% 25.53% 0.00% 35.20%
EBITDA
11,068.56 10,387.73 9,829.12 9,830.73
EBIT
11,068.56 10,387.73 9,829.12 9,830.73

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 5, 2026